Reply to Periclou et al.: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”

  • Massimo Carlo MauriEmail author
Letter to the Editor


Compliance with Ethical Standards


No external funding was used in the preparation of this reply.

Conflict of interest

Massimo Carlo Mauri has no conflicts of interest that are directly relevant to the contents of this reply.


  1. 1.
    Periclou A, Riccobene T, Kapás M, et al. Comment on: “Clinical pharmacokinetics of atypical antipsychotics: an update”. Clin Pharmacokinet. 2019. Google Scholar
  2. 2.
    Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493–528. Scholar
  3. 3.
    Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.CrossRefGoogle Scholar
  4. 4.
    Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327–38.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Carrothers T, Willavize S, Jaworowicz DJ, et al. Relationship of cariprazine plasma concentration to efficacy and safety in patients with schizophrenia or bipolar mania [poster]. American Psychiatric Association (APA) Annual Meeting; 14–18 May 2016; Atlanta. Accessed 13 June 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Clinical Psychopharmacology Unit, Department of Neuroscience and Mental Health, Clinical PsychiatryFondazione IRCCS Ca’ Granda, Ospedale Maggiore PoliclinicoMilanItaly

Personalised recommendations